Combining ingredients with plausible biological roles does not guarantee that the resulting formulation improves fertility. MOXI tested a particular mixture against placebo. Primary study
What was reported
This multicenter blinded randomized trial studied an antioxidant formulation containing L-carnitine and several other ingredients in couples with male-factor infertility. Motility, morphology, and DNA-fragmentation changes did not significantly improve versus placebo. A planned internal-pilot assessment led to recruitment stopping; the resulting sample limited conclusions about pregnancy and live birth. The observed live-birth comparison did not demonstrate benefit. Primary report
Our appraisal: preserve both the mixture and the stopping design
The unit of evidence is the tested formulation. It cannot identify the isolated contribution of each ingredient, beneficial or otherwise. Describing MOXI as a trial of L-carnitine alone would change the intervention and misrepresent the question.
Laboratory semen measures and live birth also occupy different places in the outcome pathway. Improving a surrogate does not guarantee a birth, while failure to improve the planned pilot measures can still provide a rational reason not to expand a trial.
Stopping after an internal pilot affects precision for later clinical outcomes. A nonsignificant live-birth result from the resulting sample should not be presented as proof of exact equivalence. At the same time, limited power is not evidence that a hidden benefit exists.
Fertility outcomes involve the couple and the treatment pathway. Follow-up interventions, opportunity to conceive, and female-partner eligibility are relevant to interpretation, not peripheral details.
The most defensible summary is that this formulation did not show the intended benefits on key measured outcomes under the trial's conditions. It does not establish that every antioxidant mixture is identical, but it does challenge the assumption that a nutrient-based rationale is sufficient evidence of fertility improvement.
Frequently asked questions
Was L-carnitine the only ingredient?
No.
Was there a placebo group?
Yes.
Did motility and DNA fragmentation significantly improve?
Not versus placebo.
Was recruitment stopped after a planned pilot assessment?
Yes.
Did that limit live-birth precision?
Yes.
Does a neutral result prove exact equivalence?
No.
Can the effect of one ingredient be isolated here?
No.